Trial Profile
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Fulvestrant (FASLODEX) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms CONFIRM
- Sponsors AstraZeneca
- 30 Oct 2023 Planned End Date changed from 29 Dec 2023 to 29 Mar 2024.
- 16 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 25 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.